|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-11
|
|
pubmed:abstractText |
Bazedoxifene has been shown to significantly decrease the risk of vertebral fractures in postmenopausal women. No significant effect was noted on the risk of clinical fractures, but fracture risk reduction was reported in a post hoc subgroup analysis in a high risk group categorised on the basis of BMD and prior fracture.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1873-2763
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1049-54
|
|
pubmed:meshHeading |
pubmed-meshheading:19254788-Aged,
pubmed-meshheading:19254788-Algorithms,
pubmed-meshheading:19254788-Bone Density Conservation Agents,
pubmed-meshheading:19254788-Double-Blind Method,
pubmed-meshheading:19254788-Female,
pubmed-meshheading:19254788-Fractures, Bone,
pubmed-meshheading:19254788-Humans,
pubmed-meshheading:19254788-Indoles,
pubmed-meshheading:19254788-Middle Aged,
pubmed-meshheading:19254788-Osteoporosis, Postmenopausal,
pubmed-meshheading:19254788-Postmenopause,
pubmed-meshheading:19254788-Risk Factors,
pubmed-meshheading:19254788-Spinal Fractures
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
|
|
pubmed:affiliation |
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. w.j.Pontefract@shef.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
